Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the company, Marketbeat reports.

Ipsen has expanded its oncology pipeline by licensing rights to an antibody-drug conjugate (ADC) for solid tumours from Sutro Biopharma, its first drug in the category. The deal, which has a top ...

It took clutch 3-point making and a little bit of magic for Santa Barbara to take down juggernaut Mater Dei Tuesday night.